.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,531,530

« Back to Dashboard

Details for Patent: 7,531,530

Title:Therapeutic compounds
Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Inventor(s): Helleday; Thomas (Stockholm, SE), Curtin; Nicola (Tyne and Wear, GB)
Assignee: Cancer Research Technology Limited (London, GB) Pfizer (New York, NY)
Filing Date:Jul 23, 2004
Application Number:10/565,308
Claims:1. A method for treating cancer in a mammal, wherein the cancer is of a type that is caused by a genetic defect in a gene that mediates homologous recombination and is selected from the group consisting of cancer of the: breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of: XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51, RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising: selecting the mammal having said genetic defect; and administering to the mammal a compound selected from the group consisting of a compound of the formula I, formula II and formula III: ##STR00005## or a pharmaceutically acceptable salt thereof.

2. The method according to claim 1, wherein the compound is the compound of the formula I.

3. The method according to claim 2, wherein the compound of the formula I is in the form of a phosphate salt.

4. The method of claim 1, wherein the cancer is breast cancer.

5. The method of claim 1, wherein the genetic detect is the absence of a gene encoding a protein involved in homologous recombination.

6. The method of claim 1, wherein the genetic defect is in the expression of a gene encoding a protein involved in homologous recombination.

7. The method of claim 1, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

8. The method of claim 7, wherein the tumor suppressor gene is BRCA1 and/or BRCA2.

9. A method for inducing apoptosis of cells defective in a gene that mediates homologous recombination, the cells being cancer cells selected from the group consisting of cancer cells of the: breast, lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin, the gene that mediates homologous recombination being selected from the group consisting of XRCC1, CTPS, RPA, RPA1, RPA2, RPA3, XPD, ERCC1, XPF, MMS19, RAD51, RAD51.beta., RAD51C, RAD51D, DMC1, XRCCR, XRCC3, BRCA1, BRCA2, RAD52, RAD54, RAD50, MRE11, NB51, WRN, BLM KU70, KU80, ATM, ATR CHK1, CHK2, FANCA, FANCB, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, FANCC, FANCD1, FANCD2, FANCE, FANCF, FANCG, RAD1, RAD9 and combinations thereof, the method comprising: selecting the cancer cells having said genetic defect; and administering to the cancer cells a compound selected from the group consisting of a compound of the formula I, formula II and formula III: ##STR00006## or a pharmaceutically acceptable salt thereof.

10. The method according to claim 9, wherein the compound is the compound of the formula I.

11. The method according to claim 10, wherein the compound of the formula I is in the form of a phosphate salt.

12. The method of claim 9, wherein the genetic defect of the cells is the absence of a gene encoding a protein involved in homologous recombination.

13. The method of claim 9, wherein the genetic defect of the cells is in the expression of a gene encoding a protein involved in homologous recombination.

14. The method of claim 9, wherein the gene that mediates homologous recombination is a tumor suppressor gene.

15. The method of claim 9, wherein the tumor suppressor gene is BRCA1 and/or BRCA2 and the cancer cells are selected from the group consisting of cancer cells of the: lung, colon, pancreas, stomach, ovary, cervix, breast, prostate, bone, brain, and skin.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc